Trials / Completed
CompletedNCT00807053
Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 480 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to demonstrate the efficacy of ciclesonide HFA, applied as a nasal aerosol once daily, in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ciclesonide HFA | 75 mcg Ciclesonide HFA versus Placebo |
| DRUG | Ciclesonide HFA | 150 mcg Ciclesonide HFA versus Placebo |
| DRUG | Ciclesonide HFA | 300 mcg Ciclesonide HFA versus Placebo |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2007-06-01
- Completion
- 2007-07-01
- First posted
- 2008-12-11
- Last updated
- 2016-12-05
Locations
31 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00807053. Inclusion in this directory is not an endorsement.